Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Lineage Cell Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $63.42 Mil. Lineage Cell Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $101.02 Mil.
Therefore, Lineage Cell Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.63.
The historical rank and industry rank for Lineage Cell Therapeutics's Equity-to-Asset or its related term are showing as below:
LCTX'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27 Med: 0.73 Max: 0.94
Current: 0.63
During the past 13 years, the highest Equity to Asset Ratio of Lineage Cell Therapeutics was 0.94. The lowest was 0.27. And the median was 0.73.
LCTX's Equity-to-Asset is ranked worse than 52.62% of 1564
companies
in the Biotechnology industry
Industry Median: 0.66
vs LCTX: 0.63
Lineage Cell Therapeutics Equity-to-Asset Historical Data
The historical data trend for Lineage Cell Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lineage Cell Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lineage Cell Therapeutics Equity-to-Asset Distribution
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Lineage Cell Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Lineage Cell Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Lineage Cell Therapeutics (Lineage Cell Therapeutics) Business Description
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LCTX has been successfully added to your 